SRR15069604
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- G2M_CHECKPOINT+0.250
- NOTCH_SIGNALING+0.240
- INTERFERON_ALPHA_RESPONSE+0.220
- E2F_TARGETS+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.190
- DNA_REPAIR+0.150
- MYC_TARGETS_V2+0.150
- ANGIOGENESIS+0.100
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.350
- MYOGENESIS-0.330
- XENOBIOTIC_METABOLISM-0.330
- INFLAMMATORY_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- ESTROGEN_RESPONSE_LATE-0.260
- ALLOGRAFT_REJECTION-0.250
- APOPTOSIS-0.250
- HEME_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_S71RJ8DH | ATRT | — | 0.755 |
| 2 | BS_M4923M40 | ATRT | — | 0.742 |
| 3 | BS_R5SNFB5B | high-grade glioma | — | 0.705 |
| 4 | MDT-AP-3200 | Med | Medulloblastoma | 0.704 |
| 5 | BS_TZ5D0A7R | Supratentorial Ependymoma | — | 0.704 |
| 6 | BS_Z7890YNR | Supratentorial Ependymoma | — | 0.703 |
| 7 | TCGA-63-A5MH-01A-12R-A27Q-07 | — | cohortSQ1 | 0.694 |
| 8 | SRR934887 | — | — | 0.689 |
| 9 | 3aa50a90-3e9b-4b72-aa81-7ea3bc7861a3 | — | — | 0.688 |
| 10 | 32a88c36-6b9a-483f-ad00-bf899ae279ba | — | — | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |